Drugs / GRN-300
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04711161 | Dec 2020 → Dec 2024 | ovarian neoplasm | Green3Bio, Inc. | Suspended | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRN-300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04711161 ↗ |
| Action | Inhibit | “A salt-inducible kinase (SIK) inhibitor” NCT04711161 ↗ |
| Route | Oral | “continuous twice a day dosing of oral GRN-300” NCT04711161 ↗ |
| Target | SIK2 | “SIK2/3 Inhibitor” NCT04711161 ↗ |